Overview: Procalcitonin (PCT) Marker Rapid TestIntroduction: The Procalcitonin (PCT) Marker Rapid Test is a diagnostic tool designed to detect PCT levels in serum or plasma samples, facilitating the screening of sepsis or infection. Associated with severe bacterial infections or systemic inflammatory response syndrome, this condition presents with fever, fatigue, and severe complications like septic shock if untreated, particularly in immunocompromised individuals or those with recent surgery. Per the 2023 Surviving Sepsis Campaign guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in emergency or infectious disease settings. This rapid diagnostic falls under clinical pathology and targets individuals with systemic symptoms or infection risk factors, addressing the challenge of early detection to guide antibiotic therapy or supportive care. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing mortality. Its multi-sample capability enhances its utility.Other Names: PCT Rapid Test.FDA Status: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Brahms, this test advanced infection marker detection, providing a rapid alternative to traditional assays.Purpose: The test screens for PCT to guide sepsis or infection diagnosis, assess inflammatory status, and inform treatment and prevention strategies.Test Parameters: Presence of PCT, detected with reasonable specificity to indicate bacterial infection, typically detectable in serum or plasma at elevated levels during active sepsis.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fever, fatigue, or recent surgery.Specimen: Serum 2-5 mL, Plasma 2-4 mL, collected using sterile SST or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fever, fatigue, recent infections, or prior sepsis episodes, as well as any family history of immune disorders or recent hospitalizations.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated sepsis including septic shock, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent steroid use can affect results. Correlation with blood cultures or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result indicates possible sepsis or infection, necessitating further investigation like blood cultures or infectious disease consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.Specialist Consultation: Infectious disease specialists or emergency physicians should be consulted for case management, treatment planning, and coordination with infection control programs.Additional Supporting Tests: Blood cultures, CRP, or lactate for confirmation.Test Limitations: The test may produce false positives in trauma or false negatives in viral infections, requiring a comprehensive diagnostic approach that includes clinical correlation.References: SSC Guidelines 2023, Journal of Infectious Diseases 2024, Pathology 2025.